Only available to investors: Clovis Oncology, Inc. (NASDAQ:CLVS) Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020

On 01-28-2k21 (Thursday) Shareholders tracking shares of Clovis Oncology, Inc. (CLVS) belongs to Healthcare sector and Biotechnology industry. CLVS flaunted -3.29% to reach at $7.94 during previous trading session. CLVS Inc. has a total market value of 669.82M at the time of writing – representing $88.26M outstanding shares. Turning to other widely-considered trading data, this company’s half yearly performance is observed at 29.11%. lovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.

Unaudited preliminary results include:

  • $43.0M – $43.5M in estimated Rubraca® global product revenues for the fourth quarter of 2020 compared to $38.8M for Q3 2020 and $39.3M for Q4 2019;
    • U.S. product revenues of approximately $36.3M – $36.7M and E.U. of $6.5M – $6.8M
    • Highest quarterly global and E.U. product revenues to date
  • $164.2M -$164.7M in estimated Rubraca product revenues for FY 2020 compared to $143.0M for FY 2019
  • Approximately $240M in cash and cash equivalents at December 31, 2020 which is expected to fund the Company’s operating plan into early 2023 based on current revenue and expense forecasts

Clovis plans to discuss these results with investors this week at the 39th Annual J.P. Morgan Healthcare Conference which is being held virtually January 10-14, 2021.

“We are pleased with our strong finish to a challenging year, including achieving record quarterly and annual sales,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “We believe we have set the stage for an important year in 2021, as we seek to continue to grow Rubraca sales and advance our pipeline, including plans to report top-line ATHENA monotherapy data in the second half of the year, initiate a clinical development program for FAP-2286 in the first half of the year, and show initial efficacy data for the LIO-1 lucitanib and Opdivo combination trial at a medical meeting this year.”

Clovis Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference on January 12
Clovis’ President and CEO, Patrick J. Mahaffy, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 4:30 p.m. ET. A live webcast of the presentation/Q&A session can be accessed through the investor relations section of the Company’s website at

Fourth Quarter and Full Year 2020 Financial Results Release Planned for February 23
The Company plans to report financial results for the fourth quarter and full year ended December 31, 2020 on Tuesday, February 23, 2021, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the Company’s results in greater detail.

Volume Evaluation

The USA listed company saw a recent price trade of $7.94 and 23,158,736 shares have traded hands in the session. There are 5.95M shares which are traded as an average over the last three months period.

Many investors forget that one of the defining characteristics of the stock market is that it’s a market. Buyers and sellers help determine the price of each stock, and the more buyers and sellers a particular stock has interested in it, the more liquid the market will be. Liquidity can have a profound impact on just how violently stock prices can move in either direction, and the reasons have to do with the nature of the market in a stock’s shares.

Trading volume, or volume, is the number of shares or contracts that indicates the overall activity of a security or market for a given period. Trading volume is an important technical indicator an investor uses to confirm a trend or trend reversal. Volume gives an investor an idea of the price action of a security and whether they should buy or sell the security.

Performance Levels

Looking performance record on shares of Clovis Oncology, Inc. (CLVS) we observed that the stock has seen a move -5.36% over the last 52-week trading period. The stock generated performance of 51.53% tracking last 3 months. Investors will be anxiously watching to see if things will turn around and the stock will start gaining or losing momentum over the next few months. If we look back year-to-date, the stock has performed 65.42%. Shares are at 21.13% over the previous week and 62.70% over the past month.

Analyst Views:

Fluctuating the focus to what the Wall Street analysts are projecting, we can see that the current consensus target price on shares is $7.33. Analysts often put in a lot of work to study stocks that they cover. Wall Street analysts have a consensus recommendation of 3.30on this stock. This number falls on a one to five scale where a 1 would be considered a strong buy and 5 means a strong sell, 2 shows Buy, 3 Hold, 4 reveals Sell recommendation.

Volatility Insights

Watching some historical volatility numbers on shares of Clovis Oncology, Inc. (CLVS) we can see that the 30 days volatility is presently 9.79%. The 7 days volatility is 14.95%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

The company has a beta of 1.92. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.

The Average True Range (ATR) value reported at 0.64. The average true range (ATR) is a technical analysis indicator that measures volatility by decomposing the entire range of an asset price for that period. A stock experiencing a high level of volatility has a higher ATR, and a low volatility stock has a lower ATR. The ATR may be used by market technicians to enter and exit trades, and it is a useful tool to add to a trading system. It was created to allow traders to more accurately measure the daily volatility of an asset by using simple calculations. The indicator does not indicate the price direction; rather it is used primarily to measure volatility caused by gaps and limit up or down moves. The ATR is fairly simple to calculate and only needs historical price data.

Technical Considerations

Clovis Oncology, Inc. (CLVS) stock positioned 28.74% distance from the 200-day MA and stock price situated 54.28% away from the 50-day MA while located 39.46% off of the 20-day MA.

RSI value sited with reading of 54.55. Relative Strength Index (RSI) is an extremely useful and popular momentum oscillator. The RSI compares the magnitude of a stock’s recent gains to the magnitude of its recent losses and turns that information into a number that ranges from 0 to 100. It takes a single parameter, the number of time periods to use in the calculation. In his book, Wilder recommends using 14 periods.

Observing the Technical Indicators:

Clovis Oncology, Inc. institutional ownership is held at 67.10% while insider ownership was 0.50%. As of now, CLVS has a P/S, P/E and P/B values of 4.17, 0 and 0 respectively. Its P/Cash is valued at 2.98. The Company’s net profit margin for the 12 months at 0. Comparatively, the gazes have a Gross margin 75.30%.

Profitability ratios:

Looking into the profitability ratios of CLVS stock, an investor will find its ROE, ROA, ROI standing at 263.20%, -59.30% and -76.50%, respectively.

Earnings per Share Details of Clovis Oncology, Inc.:

The EPS of CLVS is strolling at -5.24, measuring its EPS growth this year at -5.20%. As a result, the company has an EPS growth of 78.90% for the approaching year.

Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. The Company’s payout ratio was 0 and Price to free cash flow remained $0.